drugset / Trial / NCT00250120
Pharmacology Study of Aerosolized Liposomal
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the overall response rate to liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) administered by aerosolization in patients with non-small-cell lung cancer (any stage). To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive days per week X 8 weeks, every 10 weeks. To perform a pharmacology study of L9NC in the plasma, and the lungs after aerosolization. A specific protocol will be written for this part.
Timeline
- Start
- 2003-04
- Primary completion
- 2007-03
- Completion
- 2007-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rubitecan | Unknown | 0.52 mg/m2 | Inhaled |